{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:28:22Z","timestamp":1791772102458,"version":"4.3.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.phrs.2016.12.009","type":"journal-article","created":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T20:34:50Z","timestamp":1481315690000},"page":"20-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"special_numbering":"C","title":["Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas"],"prefix":"10.1016","volume":"117","author":[{"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2016.12.009_bib0005","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.12.009_bib0010","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.12.009_bib0015","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","article-title":"RAF protein-serine\/threonine kinases: structure and regulation","volume":"399","author":"Roskoski","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2016.12.009_bib0020","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.bbrc.2011.11.145","article-title":"MEK1\/2 dual-specificity protein kinases: structure and regulation","volume":"417","author":"Roskoski","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2016.12.009_bib0025","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.12.009_bib0030","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2016.12.009_bib0035","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: promises and challenges","volume":"13","author":"Samatar","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2016.12.009_bib0040","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrc4000","article-title":"MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road","volume":"15","author":"Caunt","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2016.12.009_bib0045","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2016.12.009_bib0050","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1016\/j.bbamcr.2014.09.004","article-title":"Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame","volume":"1843","author":"Gentry","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2016.12.009_bib0055","series-title":"The MD Anderson Manual of Medical Oncology","first-page":"857","article-title":"Melanoma","author":"Kim","year":"2016"},{"key":"10.1016\/j.phrs.2016.12.009_bib0060","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2016.12.009_bib0065","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.12.009_bib0070","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2016.12.009_bib0075","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2016.12.009_bib0080","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd.2016.139","article-title":"Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design","volume":"15","author":"Ostrem","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2016.12.009_bib0085","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2016.12.009_bib0090","article-title":"Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview","author":"Fischer","year":"2016","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.phrs.2016.12.009_bib0095","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/sj.bjc.6603291","article-title":"Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis","volume":"95","author":"Eisen","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2016.12.009_bib0100","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.12.009_bib0105","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrclinonc.2014.83","article-title":"The clinical development of MEK inhibitors","volume":"11","author":"Zhao","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2016.12.009_bib0110","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2016.12.009_bib0115","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.12.009_bib0120","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","article-title":"Phase II study of the MEK1\/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor","volume":"31","author":"Kim","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2016.12.009_bib0125","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.12.009_bib0130","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2016.12.009_bib0135","doi-asserted-by":"crossref","first-page":"945","DOI":"10.6004\/jnccn.2016.0101","article-title":"NCCN guidelines insights: melanoma, version 3.2016","volume":"14","author":"Coit","year":"2016","journal-title":"J. Natl. Compr. Cancer Network"},{"key":"10.1016\/j.phrs.2016.12.009_bib0140","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein kinases 6: The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2016.12.009_bib0145","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.12.009_bib0150","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1126\/science.1862343","article-title":"Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2016.12.009_bib0155","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.tibs.2010.09.006","article-title":"Protein kinases: evolution of dynamic regulatory proteins","volume":"36","author":"Taylor","year":"2011","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2016.12.009_bib0160","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.12.009_bib0165","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.12.009_bib0170","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1098\/rstb.2012.0054","article-title":"Evolution of the eukaryotic protein kinases as dynamic molecular switches","volume":"367","author":"Taylor","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.phrs.2016.12.009_bib0175","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.molcel.2004.08.024","article-title":"Regulation of protein kinases; controlling activity through activation segment conformation","volume":"15","author":"Nolen","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2016.12.009_bib0180","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/j.1460-2075.1994.tb06361.x","article-title":"Activation of MEK family kinases requires phosphorylation of two conserved Ser\/Thr residues","volume":"13","author":"Zheng","year":"1994","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2016.12.009_bib0185","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/j.1460-2075.1994.tb06424.x","article-title":"Identification of the sites in MAP kinase-1 phosphorylated by p74raf\u22121","volume":"13","author":"Alessi","year":"1994","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2016.12.009_bib0190","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.phrs.2014.06.001","article-title":"ErbB\/HER protein-tyrosine kinases: structures and small molecule inhibitors","volume":"87","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.12.009_bib0195","doi-asserted-by":"publisher","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.12.009_bib0200","doi-asserted-by":"publisher","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2016.12.009_bib0205","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.phrs.2016.09.011","article-title":"Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms","volume":"113","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.12.009_bib0210","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.12.009_bib0215","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.phrs.2016.03.012","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"107","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2016.12.009_bib0220","doi-asserted-by":"publisher","first-page":"e1001680","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2016.12.009_bib0225","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2016.12.009_bib0230","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S0022-2836(63)80091-1","article-title":"Allosteric proteins and cellular control systems","volume":"6","author":"Monod","year":"1963","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2016.12.009_bib0235","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring: 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2016.12.009_bib0240","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1021\/jm050540c","article-title":"Novel procedure for modeling ligand\/receptor induced fit effects","volume":"49","author":"Sherman","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2016.12.009_bib0245","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.pharmthera.2015.10.002","article-title":"Allosteric small-molecule kinase inhibitors","volume":"156","author":"Wu","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2016.12.009_bib0250","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2016.12.009_bib0255","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ccr.2014.03.011","article-title":"Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors","volume":"25","author":"Lito","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2016.12.009_bib0260","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Ann. Rev. Biochem."},{"key":"10.1016\/j.phrs.2016.12.009_bib0265","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1021\/jm901443h","article-title":"Through the gatekeeper door: exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2016.12.009_bib0270","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.phrs.2016.12.009_bib0275","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2016.12.009_bib0280","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0092-8674(02)00741-9","article-title":"The conformational plasticity of protein kinases","volume":"109","author":"Huse","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2016.12.009_bib0285","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding site inhibitors","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2016.12.009_bib0290","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1021\/ml200004g","article-title":"Discovery of a highly potent and selective MEK inhibitor: GSK1120212 (JTP-74057 DMSO solvate)","volume":"2","author":"Abe","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2016.12.009_bib0295","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/0008-5472.CAN-11-1515","article-title":"Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition","volume":"72","author":"Hoeflich","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2016.12.009_bib0300","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1158\/1535-7163.MCT-07-0231","volume":"6","author":"Davies","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2016.12.009_bib0305","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816313093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661816313093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T07:20:19Z","timestamp":1568618419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661816313093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":61,"alternative-id":["S1043661816313093"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2016.12.009","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2016.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}